Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain ...

Winning an FDA approval didn't buoy the company's stock for long.

While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in ...

The Trump administration may have softened its language on China to maintain a truce in their trade war, but Congress is ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...